06/06/2026
Biotech IPO activity is recovering, but remains fragile. After the post-pandemic boom and years of policy and economic uncertainty, early 2026 has brought renewed investor interest, particularly in later-stage companies.
Biotechnology’s initial public offering (IPO) market is showing signs of life again, but it remains a fragile recovery. After the extraordinary 2021 boom (fueled in part by the COVID-19 pandemic) – more than 100 biotech companies went public and raised nearly $16 billion – the door largely shu...